<?xml version="1.0" encoding="UTF-8"?>
<ref id="B54-vaccines-08-00115">
 <label>54.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Redaelli</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Franceschi</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Capocefalo</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Dâ€™Avella</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Denaro</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Cavirani</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Mucignat-Caretta</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Donofrio</surname>
    <given-names>G.</given-names>
   </name>
  </person-group>
  <article-title>Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models</article-title>
  <source>Neuro- Oncol.</source>
  <year>2012</year>
  <volume>14</volume>
  <fpage>288</fpage>
  <lpage>301</lpage>
  <pub-id pub-id-type="doi">10.1093/neuonc/nor219</pub-id>
  <?supplied-pmid 22228853?>
  <pub-id pub-id-type="pmid">22228853</pub-id>
 </element-citation>
</ref>
